Highest-materiality recent filing
Agios Q1 mitapivat revenue $20.7M; 242 AQVESME scrips; sCD sNDA plan in Q2
Worldwide mitapivat net revenue $20.7M in Q1 2026, up from $8.7M in Q1 2025.
Agios Q4 net loss $108M; AQVESME approved for thalassemia, U.S. launch started
PYRUKYND worldwide net revenue $20M in Q4 ($16M U.S., $4M ex-U.S.), up 49% YoY in U.S.
AQVESME (mitapivat) U.S. approval in thalassemia Dec 2025; commercial launch underway, product available late Jan 2026.
Agios Q3 PYRUKYND rev $12.9M (+44% YoY); net loss $103.4M; thalassemia PDUFA Dec 7
Q3 PYRUKYND net revenue $12.9M (+44% YoY vs $9.0M); 149 U.S. patients on therapy.
Analyst report on Aug 4, 2025 references four FAERS cases; Agios says benefit-risk profile unchanged.
Agios Q2 2025 net loss $112M; PYRUKYND revenue $12.5M; PDUFA Sept 7 for thalassemia
Net loss $112.0M vs $96.1M YoY; PYRUKYND net revenue $12.5M, up from $8.6M in Q2 2024.
Agios Q1 PYRUKYND revenue $8.7M; PDUFA Sept 7 for thalassemia; net loss $89.3M
PYRUKYND net revenue $8.7M in Q1 2025 vs $8.2M in Q1 2024; 136 patients on therapy.
Agios Q4: PYRUKYND revenue $10.7M, mitapivat PDUFA Sept 7, 2025; cash $1.5B
PYRUKYND net revenue $10.7M in Q4 (+20% QoQ), full year $36.5M vs $26.8M in 2023.
Agios announces 2025 milestones: PYRUKYND PDUFA Sept 7; RISE UP topline in late 2025
FDA accepted sNDA for PYRUKYND in thalassemia; PDUFA goal date September 7, 2025.
FDA adds liver injury warning to PYRUKYND label for PK deficiency
FDA approved update to PYRUKYND USPI: liver injury observed in patients with another condition at higher doses.
Agios reports Q3 net income of $947.9M on $1.1B milestone payments; PYRUKYND rev $9.0M
Net income $947.9M vs loss $91.3M YoY; driven by $1.1B payments from Royalty Pharma & Servier.
Agios Q2 2024 net loss $96.1M; PYRUKYND rev $8.6M; plans thalassemia sNDA by year-end
PYRUKYND net revenue $8.6M in Q2 2024, up 5% sequentially; 128 patients on therapy.
Agios sells vorasidenib royalty rights to Royalty Pharma for $905M upfront upon FDA approval
Royalty Pharma pays $905M to Agios upon FDA approval of vorasidenib (PDUFA date Aug 20, 2024).
Agios Q1 2024 PYRUKYND revenue $8.2M; net loss $81.5M; mitapivat ENERGIZE-T readout Q2
PYRUKYND net revenue $8.2M in Q1 2024, up 15% sequentially; 120 patients on therapy.
Agios Q4 net loss $95.9M; positive mitapivat Phase 3 for NTD thalassemia
Q4 PYRUKYND US net revenue $7.1M (down 4% QoQ); full year 2023 $26.8M.
Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent thalassemia met primary endpoint (data Jan 3, 2024).
Agios Q3: PYRUKYND rev $7.4M; first patient dosed in Phase 3 sickle cell; net loss $91.3M
PYRUKYND net revenue $7.4M in Q3 2023 (+10% QoQ); 100 patients on therapy, 160 completed enrollment forms.
Agios Q2 2023: PYRUKYND revenue $6.7M; net loss $83.8M; pipeline advances
PYRUKYND net revenue $6.7M in Q2, up 20% QoQ; 147 patients completed enrollment forms, 99 on therapy.
Agios Q1 2023: PYRUKYND revenue $5.6M, net loss improves to $81M, cash $1.0B
PYRUKYND net revenue of $5.6M in Q1 2023; 127 unique patients enrolled, 89 on therapy.
Agios Q4 2022 net income $36.5M on PYRUKYND revenue $4.3M; cash $1.1B
PYRUKYND net revenue $4.3M in Q4 2022, $11.7M full year; 78 patients on therapy, up 39% QoQ.
Five ongoing pivotal PYRUKYND trials in thalassemia, sickle cell, and pediatric PK deficiency.
Agios appoints Tsveta Milanova as CCO effective Jan 3, 2023; Richa Poddar departs Dec 31, 2022
Tsveta Milanova named Chief Commercial Officer, will succeed Richa Poddar effective Jan 3, 2023.
Agios Q3 2022: PYRUKYND revenue $3.5M, 56 patients on therapy; CHMP positive opinion received
PYRUKYND net revenue $3.5M in Q3 2022; 56 patients on therapy (+51% Q/Q), 84 patients enrolled (+64%).
Agios sells TIBSOVO royalty rights to Sagard for $131.8M upfront
Upfront cash payment of $131.8M for 5% royalty on U.S. net sales of TIBSOVO (ivosidenib).
Agios appoints Cecilia Jones as CFO effective Sept 26; replaces Jonathan Biller
Cecilia Jones appointed CFO, effective Sept 26, 2022, replacing Jonathan Biller who resigned Sept 16 to become CLO at Vertex.
Agios Pharma CFO Jonathan Biller resigns effective Sept 16
Jonathan Biller notified resignation as CFO, head of corporate affairs, effective Sept 16, 2022.
Agios appoints Brian Goff as CEO; Jackie Fouse transitions to Chair effective Aug 8, 2022
CEO Brian Goff appointed effective Aug 8, 2022; current CEO Jackie Fouse becomes Chair of Board.
Agios CSO Bruce Car resigns, signs consulting agreement through March 2023
Dr. Bruce Car steps down as chief scientific officer effective August 1, 2022.
Agios reports Q1 net loss $94.8M; PYRUKYND launch revenue $0.8M, cash $1.2B
FDA approved PYRUKYND for PK deficiency in Feb 2022; U.S. launch generated $0.8M net revenue in partial quarter.
Agios Q4 net loss $98.6M; FDA approved PYRUKYND for PK deficiency; cash $1.3B
Net loss $98.6M in Q4 2021 vs $84.5M in Q4 2020; full-year net loss $356.5M.
Agios Q3 net loss $88.8M; mitapivat gets FDA Priority Review with PDUFA Feb 17, 2022
Net loss $88.8M vs $99.0M in Q3 2020; R&D $64.0M up from $51.9M on trial start-up costs.
Agios Q2 net loss $86.2M, cash $1.7B; CMO retirement, mitapivat NDA submitted
Net loss $86.2M vs $90.5M; cash, cash equivalents and marketable securities $1.7B.
On February 10, 2025, David P. Schenkein, M.D., notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective February 28, 2025.
John Maraganore, Ph.D., notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective May 24, 2023
elected Catherine Owen as a director, effective as of June 13, 2023
appointed director Kaye Foster to serve as the Board’s lead independent director
On April 17, 2023, Paul Clancy notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision not to stand for re-election to the Board of Directors (the “Board”) of the Company when his current term expires at the Company’s 2023 Annual Meeting of Stockholders.
On April 18, 2023, the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Corporate Governance Committee”), elected Jeff Capello as a director, effective as of the date of the Corporation’s 2023 Annual Meeting of Stockholders (the “Effective Date”).
the Company appointed Tsveta Milanova as the Company’s Chief Commercial Officer, effective as of January 3, 2023
On September 15, 2022, the Board of Directors (the “Board”) of Agios Pharmaceuticals, Inc. (the “Company”) appointed Cecilia Jones as the Company’s Chief Financial Officer effective as of September 26, 2022 (the “Effective Date”).
On September 6, 2022, Jonathan Biller notified the Company of his intention to resign as chief financial officer, head of corporate affairs and principal financial officer of the Company, effective September 16, 2022, in order to pursue other opportunities.
On August 11, 2022, the Board of Directors (the “Board”) of Agios Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee (the “Corporate Governance Committee”), elected Rahul Ballal, Ph.D. and Cynthia Smith as directors.
On August 11, 2022, the Board of Directors (the “Board”) of Agios Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee (the “Corporate Governance Committee”), elected Rahul Ballal, Ph.D. and Cynthia Smith as directors.
Jacqualyn A. Fouse, Ph.D. will resign from the position of Chief Executive Officer and will assume the role of Chair of the Board of Directors
Max materiality 0.85 · Median 0.62 · Most common event earnings